As of 9:07:20 AM GMT+1. Market Open.
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| Currency in GBP | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 2 | 6 | 6 |
| Avg. Estimate | 3.73M | 3.05M | 20.75M | 28.03M |
| Low Estimate | 1.2M | 1.1M | 14.9M | 4.2M |
| High Estimate | 5M | 5M | 30M | 86.59M |
| Year Ago Sales | 2.1M | 12.41M | 25.38M | 20.75M |
| Sales Growth (year/est) | 77.86% | -75.42% | -18.23% | 35.10% |
EPS Trend
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| XRP2.F | -- | -- | -- | -- |
| S&P 500 | 8.70% | 11.55% | 14.03% | 13.42% |
Upgrades & Downgrades
| Maintains | Chardan Capital: Buy to Buy | 12/10/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 12/9/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 11/20/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 11/15/2024 |
| Maintains | Chardan Capital: Buy to Buy | 11/14/2024 |
| Reiterates | Morgan Stanley: Overweight to Overweight | 10/8/2024 |
Related Tickers
7IZ.MU Ziccum AB
0.0298
-29.72%
IKAP.MU Aurinia Pharmaceuticals Inc
8.14
0.00%
HQ1.MU Oruka Therapeutics Inc. R
18.60
0.00%
5KW.F SkinBioTherapeutics plc
0.1660
-2.35%
ORN.F Oryzon Genomics S.A.
1.5020
+2.18%
BLE.BE bluebird bio Inc
0.3708
-3.01%
41X.F Ardelyx, Inc.
5.12
+0.16%
PH4.F CStone Pharmaceuticals
0.2640
-1.49%
ALGEN.PA genOway Société anonyme
3.9000
+1.04%
0WA2.IL Cellectis S.A.
1.8720
+5.52%